Architectural Heterogeneity in Tumors Caused by Differentiation
Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound
Figure 5
Response to cytotoxic drugs alone and in combination with MSC in H69 lung xenografts when treatment was started at ~100 mm3 tumor volume (a), at ~1000 mm3 tumor volume (b), and in human surgical samples of HNSCC WDSCC and PDSCC.